Reduced vital capacity (HP:0002792)
An abnormal reduction on the vital capacity, which is defined as the total lung capacity (volume of air in the lungs at maximal inflation) less the residual volume (i.e., volume of air in the lungs following maximal exhalation) of the lung.
Synonyms: Decreased vital capacity
Cross References: SNOMEDCT_US:274715008, SNOMEDCT_US:607007, UMLS:C0476408, UMLS:C0520831
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Neuroactive ligand-receptor interaction | 0.00001608 | 0.0001286 | 38.88 | 429.14 |
| 2 | Viral myocarditis | 0.02960 | 0.07518 | 37.53 | 132.12 |
| 3 | Cardiac muscle contraction | 0.04267 | 0.07518 | 25.72 | 81.12 |
| 4 | Hypertrophic cardiomyopathy | 0.04411 | 0.07518 | 24.85 | 77.54 |
| 5 | Dilated cardiomyopathy | 0.04699 | 0.07518 | 23.27 | 71.15 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | synaptic transmission, cholinergic (GO:0007271) | 8.685e-8 | 0.000001795 | 535.02 | 8698.92 |
| 2 | neuromuscular junction development (GO:0007528) | 1.812e-7 | 0.000002381 | 407.53 | 6326.45 |
| 3 | muscle contraction (GO:0006936) | 1.316e-11 | 8.161e-10 | 242.28 | 6070.00 |
| 4 | neuromuscular process (GO:0050905) | 0.00003830 | 0.0002638 | 293.72 | 2987.15 |
| 5 | postsynaptic membrane organization (GO:0001941) | 0.00003830 | 0.0002638 | 293.72 | 2987.15 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential (GO:0099529) | 1.878e-10 | 5.070e-9 | 783.25 | 17541.62 |
| 2 | transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential (GO:1904315) | 8.580e-10 | 1.158e-8 | 511.90 | 10686.61 |
| 3 | transmitter-gated ion channel activity (GO:0022824) | 1.451e-9 | 1.305e-8 | 443.56 | 9026.96 |
| 4 | postsynaptic neurotransmitter receptor activity (GO:0098960) | 1.191e-7 | 7.447e-7 | 475.52 | 7581.26 |
| 5 | acetylcholine receptor activity (GO:0015464) | 1.379e-7 | 7.447e-7 | 450.47 | 7115.97 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | neuromuscular junction (GO:0031594) | 4.712e-12 | 8.481e-11 | 604.76 | 15772.67 |
| 2 | acetylcholine-gated channel complex (GO:0005892) | 3.267e-8 | 2.940e-7 | 778.40 | 13417.28 |
| 3 | ion channel complex (GO:0034702) | 5.841e-7 | 0.000003505 | 267.29 | 3836.51 |
| 4 | myosin filament (GO:0032982) | 0.002997 | 0.008990 | 444.11 | 2580.41 |
| 5 | muscle myosin complex (GO:0005859) | 0.007476 | 0.01892 | 158.54 | 776.21 |
Hub genes predicated as biomarkers & FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| RAPSN | – |
| CHRNA1 | – |
| CHRND | SUCCINYLCHOLINE CHLORIDE, PIPECURONIUM BROMIDE, MIVACURIUM CHLORIDE, METOCURINE IODIDE, DOXACURIUM CHLORIDE, VECURONIUM BROMIDE, DECAMETHONIUM BROMIDE |
| CHRNE | SUCCINYLCHOLINE CHLORIDE, PIPECURONIUM BROMIDE, MIVACURIUM CHLORIDE, METOCURINE IODIDE, DOXACURIUM CHLORIDE, VECURONIUM BROMIDE, DECAMETHONIUM BROMIDE |
| CHRNB1 | SUCCINYLCHOLINE CHLORIDE, PIPECURONIUM BROMIDE, MIVACURIUM CHLORIDE, METOCURINE IODIDE, DOXACURIUM CHLORIDE, VECURONIUM BROMIDE, DECAMETHONIUM BROMIDE |
| DOK7 | – |
| MUSK | – |
| SCN4A | LEVOBUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE |
| ACTA1 | – |
| MYH7 | – |
